Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?
Diego González Cabrera, Dennis A. Smith, Gregory S. Basarab, James Duffy, Thomas Spangenberg, Kelly Chibale
Abstract
This viewpoint outlines the case for developing new chemical entities (NCEs) as racemates in infectious diseases and where both enantiomers and racemate retain similar on- and off-target activities as well as similar PK profiles. There are not major regulatory impediments for the development of a racemic drug, and minimizing the manufacturing costs becomes a particularly important objective when bringing an anti-infective therapeutic to the marketplace in the endemic settings of infectious diseases.
Topics & Concepts
EnantiomerDrugNorm (philosophy)Drug developmentComputer scienceBusinessRisk analysis (engineering)MedicineComputational biologyBiochemical engineeringPharmacologyBiologyChemistryPolitical scienceStereochemistryEngineeringLawAnalytical Chemistry and ChromatographyPharmacogenetics and Drug MetabolismDrug Transport and Resistance Mechanisms